Iðunn

Overview

Iðunn is a venture capital fund managed by Kvika Asset Management, established in March 2021 with a size of ISK 7.3 billion. The fund specializes in investments within the life sciences and health technology sectors, emphasizing long-term growth and sustainability. Its investment period spans five years, targeting companies with robust business development plans and management capabilities to drive growth and prepare for scaling. The fund's portfolio includes investments in Coripharma, a manufacturer of generic drugs for the European market; EpiEndo Pharmaceuticals, focused on developing treatments for chronic lung diseases; Kara Connect, a digital health platform connecting health professionals with clients; NeckCare, a device supporting objective assessment and personalized rehabilitation for neck injuries; and PLAIO, an AI-driven software for pharmaceutical and biotech companies. In 2024, Iðunn led a €4.3 million investment in PLAIO. Iðunn's investment strategy involves active participation in the strategic development of its portfolio companies, often through board involvement, to maximize long-term value. The fund encourages its investees to demonstrate social responsibility, adhere to good corporate governance, and consider environmental issues in their operations. This approach aligns with Kvika Asset Management's commitment to long-term performance and sustainability in its investment practices.

Investment Focus

• Companies in life sciences and health technology sectors
• Strong business development plans
• Management teams capable of scaling operations

Portfolio Companies